Top-News

Inhibrx Biosciences Aktie News

Aktie
WKN:  A40C2U ISIN:  US45720N1037 US-Symbol:  INBX Branche:  Biotechnologie Land:  USA
79,59 $
-2,62 $
-3,19%
67,793 € 12.12.25
Depot/Watchlist
Marktkapitalisierung *
1,11 Mrd. €
Streubesitz
7,31%
KGV
0,13
Index-Zuordnung
-

Inhibrx Biosciences News

14.11.25 - PR Newswire
Inhibrx Reports Third Quarter 2025 Financial Results
Inhibrx Reports Third Quarter 2025 Financial Results PR Newswire
04.11.25 - PR Newswire
Inhibrx Announces Participation in Upcoming Scientific Conferences
Inhibrx Announces Participation in Upcoming Scientific Conferences PR Newswire
23.10.25 - PR Newswire
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and ...
22.10.25 - PR Newswire
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer ...
13.08.25 - PR Newswire
Inhibrx Reports Second Quarter 2025 Financial Results
Inhibrx Reports Second Quarter 2025 Financial Results PR Newswire
14.05.25 - PR Newswire
Inhibrx Reports First Quarter 2025 Financial Results
Inhibrx Reports First Quarter 2025 Financial Results PR Newswire
01.04.25 - PR Newswire
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President PR Newswire
21.01.25 - PR Newswire
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer PR Newswire
13.01.25 - PR Newswire
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance PR Newswire

Newssuche

Videos

newspaper
12.12.25 +5,87%
Technical Trading: Neues Allzeithoch im Visier
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »